Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Banks Lobby RBI: Massive Loan Provisioning Rule Change Brewing! Will Profits Skyrocket?

Banking/Finance

|

Updated on 11 Nov 2025, 07:14 pm

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

Commercial banks are urging the Reserve Bank of India (RBI) to reduce the proposed provisioning for Stage-II loans under the new Expected Credit Loss (ECL) framework. Banks want the floor lowered from the suggested 5% to closer to the current 0.4%, arguing the higher requirement could significantly impact their profitability.
Banks Lobby RBI: Massive Loan Provisioning Rule Change Brewing! Will Profits Skyrocket?

▶

Detailed Coverage:

Commercial banks are preparing to lobby the Reserve Bank of India (RBI) regarding the draft Expected Credit Loss (ECL) framework for loan-loss provisioning. A key point of contention is the proposed minimum provisioning requirement for Stage-II loans. Currently, under the incurred-loss regime, banks typically provision around 0.4% for such loans, which often include Special Mention Accounts 1 or 2 (SMA1/SMA2). The RBI's draft ECL framework, however, has set a floor of 5% for Stage-II loan provisioning. Banks argue this substantial increase to 5% will disproportionately hit their profitability and capital adequacy. They are seeking the RBI to lower this minimum requirement, suggesting a figure closer to the current provisioning levels.

Difficult Terms: * **Provisioning**: Banks set aside a portion of their profits as a reserve to cover potential losses from loans that might default. * **Stage-II loans**: Loans that have experienced a significant increase in credit risk since they were initially granted, but are not yet considered defaulted. These often include accounts showing early signs of stress. * **Expected Credit Loss (ECL)**: A forward-looking accounting standard that requires banks to estimate and account for potential loan losses over the life of the loan, rather than waiting for a loss to be incurred. * **Incurred-loss regime**: The current system where provisions are made only when a loss is incurred or is highly probable. * **Special Mention Accounts (SMA1/SMA2)**: Categorizations for loans that are becoming delinquent. SMA1 loans are overdue between 1 to 30 days, while SMA2 loans are overdue between 31 to 60 days. * **Loan exposure**: The total amount of money a bank has lent out to a borrower.

**Impact**: This news is highly relevant to the Indian banking sector. A change in provisioning rules directly affects banks' profitability, balance sheets, and potentially their stock market valuations. Investors closely watch such regulatory discussions as they can lead to significant shifts in financial performance for major banks. Rating: 8/10.


Healthcare/Biotech Sector

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!


Agriculture Sector

Adani Wilmar Deal SHOCKER: Wilmar Buys Big Stake! What It Means For Your Money Now?

Adani Wilmar Deal SHOCKER: Wilmar Buys Big Stake! What It Means For Your Money Now?

Adani Group's Strategic Exit: Wilmar International Secures Major Stake in AWL Agri Business!

Adani Group's Strategic Exit: Wilmar International Secures Major Stake in AWL Agri Business!

Adani Wilmar Deal SHOCKER: Wilmar Buys Big Stake! What It Means For Your Money Now?

Adani Wilmar Deal SHOCKER: Wilmar Buys Big Stake! What It Means For Your Money Now?

Adani Group's Strategic Exit: Wilmar International Secures Major Stake in AWL Agri Business!

Adani Group's Strategic Exit: Wilmar International Secures Major Stake in AWL Agri Business!